ticlopidine has been researched along with Intestinal Obstruction in 2 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Intestinal Obstruction: Any impairment, arrest, or reversal of the normal flow of INTESTINAL CONTENTS toward the ANAL CANAL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups." | 2.82 | Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016) |
| "Treatment with ticlopidine, a platelet-aggregation inhibitor (250 mg twice daily), was initiated and she has now been free of extracutaneous symptoms for 6 years." | 2.39 | [Malignant atrophic papulosis]. ( Aumiller, J; Kutzner, H; Ostendorf, PC; Saeger, W; Voigt, C, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vaduganathan, M | 1 |
| Bhatt, DL | 1 |
| Cryer, BL | 1 |
| Liu, Y | 1 |
| Hsieh, WH | 1 |
| Doros, G | 1 |
| Cohen, M | 1 |
| Lanas, A | 1 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Laine, L | 1 |
| Cannon, CP | 1 |
| Voigt, C | 1 |
| Aumiller, J | 1 |
| Saeger, W | 1 |
| Kutzner, H | 1 |
| Ostendorf, PC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ticlopidine and Intestinal Obstruction
| Article | Year |
|---|---|
[Malignant atrophic papulosis].
Topics: Biopsy; Combined Modality Therapy; Female; Humans; Intestinal Obstruction; Intestinal Perforation; J | 1994 |
1 trial available for ticlopidine and Intestinal Obstruction
| Article | Year |
|---|---|
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; | 2016 |